We uncover the ideal patient, their diagnostic and treatment journey, and healthcare provider ecosystem to commercialize life-saving therapies for speciality and rare disease
Who is my target patient population? What is their diagnostic and treatment journey? How large is the market for my candidate or expanded-use therapy?
Who are my medically eligible patients to recruit for study? Around which sites do these patient clusters exist? Which HCPs are most engaged for investigator selection?
How do we focus on the highest value patient targets and maximize engagement channels with HCPs for disease interception and therapy intervention?
Discovering diagnosed, misdiagnosed and undiagnosed patients through machine learning, artificial intelligence and evolutionary computation applied to a real world data universe of over 300 million de-identified patient journeys and 65 billion anonymized social determinants of health signals refreshed weekly.
Our unparalleled ability to demonstrate empirical results is rooted in our unique combination of a granular RWD universe, decades of in-house consulting, technology and domain expertise, as well as a modern machine learning and artificial intelligence infrastructure.
Whether seeking patients yet to be diagnosed with a rare or specialty disease, ready to progress to your 2nd or 3rd line therapy or at risk of non-adherence, our solutions focus on developing the business rules to isolate the ideal patient population, leveraging ML/AI to predict the lookalike audience at scale and associate physicians via several different attribution techniques.
We examine the pathways and critical moments across the continuum of care to address various questions related to both the patient experience (e.g., demographics, co-morbidities, prior treatment, diagnostic testing, signs and symptoms) and the provider dynamics (e.g., place of service, specialty and payer makeup) to provide a high-definition view of leverage points.
While the industry has historically used field intelligence, primary research and secondary data to understand healthcare providers, we place the patient at the center of all analysis and draw on years of granular-level patient-provider interaction data to effectively map treating physicians, referral patterns and key opinion leaders for disease states.
Simply put, we really value our partnership with IPM.ai
Shortening the Rare Disease Diagnostic Odyssey is filled with proven methodologies, use cases and success stories on how pharmaceutical companies can identify, engage and educate ideal patients who could benefit from innovative therapies and modalities of care.